Aim: To evaluate the safety and tolerability of dapagliflozin, a highly selective sodium-glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus (T2DM).
renal glucose reabsorption and increasing urinary glucose excretion. [4] [5] [6] In phase III trials, dapagliflozin was efficacious and well tolerated in the early and late stages of T2DM, with no major imbalances in safety events observed between the dapagliflozin and control arms. [7] [8] [9] [10] [11] Although the CV safety of SGLT2 inhibitors has been confirmed in recent outcome trials, pooled analyses of these agents have previously shown differing overall safety profiles. Empagliflozin was well tolerated with no increase in the risk of hypoglycaemia (except in patients on background sulphonylureas) and UTI and volume depletion (except in patients aged ≥75 years, where a higher incidence was observed with both empagliflozin 10 and 25 mg) compared with placebo. 12, 13 Low rates of bone fractures, AEs consistent with decreased renal function and diabetic ketoacidosis (DKA) were observed in the empagliflozin and placebo groups. 12, 13 Small increases in serum creatinine and small decreases in estimated glomerular filtration rate (eGFR) were noted across the overall pool of patients, with larger changes in the empagliflozin groups compared with placebo. Genital infections were more frequent with empagliflozin vs placebo. Canagliflozin was associated with a slightly higher incidence of hypoglycaemia vs the comparator. Also, higher incidences of genital infections, UTI and AEs related to volume depletion were observed with canagliflozin vs comparator. 14 The incidence rates of fractures and DKA were low in the canagliflozin and comparator groups. 14 Over the past couple of years, drug safety communications regarding the risk of DKA, fracture and serious UTIs of pyelonephritis, urosepsis and acute kidney injury related to the use of SGLT2 inhibitors have been issued by the US Food and Drug Administration (FDA). 15, 16 Another drug safety communication was also issued more recently regarding the potential for an increased risk of lower limb amputation (mostly affecting the toes) in patients receiving canagliflozin, 17 prompted by an increase in lower limb amputation reported in an interim analysis of the CANVAS trial in patients with T2DM with a history/risk of CV disease. 18 This was further confirmed in the final analysis of the CANVAS programme, which showed increased risk of lower limb amputation with canagliflozin vs placebo (6.3 vs 3.4 per 1000 patient-years; hazard ratio 1.97; 95%
confidence interval [CI] 1.41 to 2.75). 1 The present analysis builds on a previous publication on the safety of dapagliflozin 19 by evaluating the safety and tolerability of dapagliflozin in a larger pool of studies and reporting the incidence of amputation and DKA, which were not included in the previous analyses.
2 | METHODS
| Patient population
Three pooled patient populations were included in this analysis. The majority of AEs were evaluated using pooled data from 13 placebocontrolled, double-blind, phase IIb/III studies of up to 24 weeks' duration ( Figure S1 ), in which patients with T2DM were randomized to receive dapagliflozin 10 mg (N = 2360) or placebo (N = 2295). This included 3 phase IIb studies of 12 weeks' duration, and 10 phase III studies of 24 weeks' duration. The placebo-controlled pool was analysed to better enable identification of any difference in the frequency of AEs with dapagliflozin vs placebo. (ClinicalTrials.gov identifiers: NCT00263276, NCT00357370, NCT00528372, NCT00528879,   NCT00643851, NCT00660907, NCT00663260, NCT00831779,   NCT00673231, NCT00680745, NCT00683878, NCT00736879,   NCT00855166, NCT00859898, NCT00972244, NCT00976495,   NCT00984867, NCT01031680, NCT01042977, NCT01095653,   NCT01095666, NCT01137474, NCT01195662, NCT01217892,   NCT01294423, NCT01294436, NCT01392677, Figure S3 ). The 21-study pool had the same data cut as for the 13-study pool. Additional studies were analysed for amputations that were not part of the dapagliflozin clinical programme (such as those with a study group receiving saxagliptin plus dapagliflozin). In these two pools, the doses of dapagliflozin given across all studies were 2.5, 5, 10, 20 and 50 mg; however, dapagliflozin 5 and 10 mg were the most frequently used doses.
| Outcomes
The outcomes analysed in the 13-study pool were overall AEs and serious AEs (SAEs), AEs occurring in ≥3% of the pooled population, 
| Statistical analysis
All patients who received at least 1 dose of study treatment were included in the analyses. The analyses were post hoc and no statistical hypothesis testing was performed. Descriptive statistics were used to describe safety parameters and all analyses were performed using all available data regardless of rescue during the specified treatment period.
| Ethical approval
All studies were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All enrolled patients provided written informed consent before entering the trial.
3 | RESULTS
| Patient disposition
Patient baseline characteristics were generally similar in the dapagliflozin and control groups in the studies included in the 3 study pools (data for the 13-and 21-study pools are shown in Table S1 ). As data for the 30 studies were not formally pooled, baseline data tables are not available for this pool. In the 13-study pool, at baseline, the mean duration since T2DM diagnosis was 8.9 years, the mean glycated haemoglobin (HbA1c) value was 8.2% (66 mmol/mol), the mean systolic blood pressure was 132 mm Hg and the majority of patients (>85%) had an eGFR ≥60 mL/min/1.73 m 2 . Over 90% of patients had a body mass index ≥25 kg/m 2 . Overall, 10.0% and 11.6% of dapagliflozin-and placebo-treated patients, respectively, were treated with loop diuretics.
3.2 | Overall AEs: 13-study pool
The overall incidence of AEs is shown in 3.3 | AEs of special interest: 13-study pool
The overall incidence of hypoglycaemia was 13.7% and 12.4% with dapagliflozin and placebo, respectively ( Table 2 ). Major hypoglycaemia occurred infrequently, with 3 and 2 events reported with dapagliflozin and placebo, respectively. Most of the events of major hypoglycaemia occurred in patients receiving insulin as background therapy. Only 1 patient in the dapagliflozin group discontinued treatment because of hypoglycaemia. This patient was receiving dapagliflozin added to insulin and metformin, and discontinued treatment after reporting major hypoglycaemia on day 107.
| AEs of renal function
Overall, AEs of renal function were reported in 76 (3.2%) and 42 (1.8%) patients receiving dapagliflozin and placebo, respectively. A greater number of events of decreased renal creatinine clearance or renal impairment were observed with dapagliflozin ( Table 2; Table S2) (Table S2) . When stratified by age, AEs of renal function were more frequent in patients aged ≥65 years than in those aged <65 years (Table S2 ).
In patients receiving dapagliflozin, there was an initial decline in eGFR at week 1 ( Figure 1 ), followed by a return towards baseline levels over time (mean change from baseline at week 24: −1.45 and −0.67 mL/min/1.73 m 2 with dapagliflozin and placebo, respectively).
The change from baseline over time was consistent in the overall study population and in patients with baseline eGFR ≥60 mL/min/ 1.73 m 2 ; however, compared with patients with a higher baseline eGFR, dapagliflozin-treated patients with an eGFR of 30 to <60 mL/ min/1.73 m 2 had a smaller reduction in eGFR at week 1, which returned to baseline by week 4 ( Figure S4 ).
| Volume depletion
The incidence of AEs of volume depletion (hypotension/hypovolemia/ dehydration) was 1.1% and 0.7% with dapagliflozin and placebo, respectively ( Table 2 ). In both treatment groups, half of the AEs of volume depletion occurred by week 8, with 18.5% (5/27) and 17.6%
(3/17) occurring during the first 2 weeks of treatment in the dapagliflozin and placebo groups, respectively. When stratified by age, the frequency of AEs of volume depletion was similar in patients aged <65
and ≥65 years in the placebo group, whereas in the dapagliflozin group, patients aged ≥65 years were more likely to have an AE of volume depletion (Table S3 ). The frequency of AEs of volume depletion in patients using loop diuretics was 2.5 times higher than in patients not using them in both treatment groups (Table S3 ). In addition, AEs of volume depletion occurred less frequently in patients with baseline eGFR ≥60 mL/min/1.73 m 2 than in those with baseline eGFR 30 to <60 mL/ min/1.73 m 2 regardless of the treatment group (Table S3) .
Hypotension was the most common AE of volume depletion in both treatment groups; however, most events were considered unrelated to study drug, were of mild/moderate intensity and did not require drug interruption/discontinuation. Syncope was the second most frequently reported AE of volume depletion, with episodes of syncope distributed throughout the 24-week treatment period (Table S4 ).
| Urinary tract infection
The occurrence of UTI was 4.7% and 3.5% with dapagliflozin and placebo, respectively (Table 2) , and UTIs were more frequent in women than men in both treatment groups (Table S5) (Table S5 ).
| Genital infection
Genital infections were more frequent with dapagliflozin vs placebo (5.5% vs 0.6%). More women than men experienced genital infections in both treatment groups ( (Table S5 ).
| Fracture
The proportion of patients reporting fractures was small in both the dapagliflozin (8 [0.3%]) and placebo (17 [0.7%]) groups ( Table 2 ). The most common fracture locations were the foot, ankle, femoral neck, hand, radius, upper limb and spine (Table S6 ). There was no consistent pattern to fracture location in either group.
| Lipids
Small mean increases from baseline in HDL cholesterol (0.07 mmol/L), LDL cholesterol (0.07 mmol/L) and total cholesterol (0.11 mmol/L) were observed, whereas a small decrease in triglycerides (−0.07 mmol/ L) was noted (Table S7 ).
| DKA: 21-study pool
One SAE of DKA, 2 AEs of ketonuria and 1 AE of metabolic acidosis were reported in the dapagliflozin group and none in the control group ( Table 2 ). The estimated incidence of DKA/metabolic acidosis with dapagliflozin was 0.03% (95% CI 0.010-0.089) and the estimated incidence of DKA alone was 0.02% (95% CI 0.004-0.059). The SAE of DKA occurred in a patient who was receiving dapagliflozin 10 mg added to metformin and insulin. An event of gastroenteritis was also recorded in this patient on the same day (day 214), and both DKA and gastroenteritis were considered unrelated to the study drug.
Treatment was continued after the event resolved.
| Amputation: 30-study pool
Lower limb amputation (ie, leg and foot amputation, mostly affecting the toes) was reported for 8 (0.1%) and 7 (0.2%) dapagliflozin-and control-treated patients, respectively (Table 2 ). There were no apparent between-group differences in the baseline characteristics of patients who had an amputation. In both groups, patients who had an amputation had a high prevalence of risk factors for amputation, including neuropathy, CV disease, dyslipidaemia and nephropathy. Time to amputation was similar for dapagliflozin-and control-treated patients.
In the dapagliflozin group, the onset of events occurred >150 days after initiation of study treatment in the majority (5/8) of patients. In our pooled analysis, eGFR did not return to baseline in the overall population treated with dapagliflozin, possibly because of the relatively short duration of treatment; however, in longer-term dapagliflozin studies, the initial decline in eGFR was observed to return to near-or above-baseline levels by week 24 that remained stable to week 102. 23 This finding correlates with the findings noted in the empagliflozin and canagliflozin trials. In the EMPA-REG OUTCOME trial, a short-term eGFR decrease followed by stabilization over time was observed for empagliflozin (median treatment duration 2.6 years, median observation time 3.1 years). 24 Likewise, an initial decrease in eGFR (3-6 weeks)
that attenuated over time has also been observed for canagliflozin. 25 Osmotic diuresis caused by SGLT2 inhibition may potentially lead to volume depletion in susceptible patients; however, the incidence of volume depletion was low in our analysis and analyses of the currently marketed SGLT2 inhibitors have demonstrated that the risk of these events lessens over time. 14, 26 The incidence of events of volume depletion was observed to be low with empagliflozin 10 and 25 mg and placebo (1.8, 1.9 and 1.7 per 100 patient-years, respectively), with an increased incidence of events observed in patients aged ≥75 years (3.2, 3.0 and 2.3 per 100 patient-years, respectively) and those receiving loop diuretics (5.0, 4.4 and 3.5 per 100 patientyears, respectively). 13 The incidence of events of volume depletion over 104 weeks was 2.9%, 3.6% and 2.1% with canagliflozin 100 and 300 mg and control, respectively. 14 In the CANVAS trial, the inci- with empagliflozin 10 and 25 mg and placebo, respectively. 13 The incidence rates of UTIs were 7.7, 6.8 and 6.4 per 100 patient-years with canagliflozin 100 and 300 mg and placebo, respectively. In the present analysis, there was only 1 reported SAE of DKA. It may have occurred in response to insulin dose reduction, which is considered as a precipitant of DKA. 34 In a pooled analysis of empagliflozin studies (n = 12 620), incidence rates of DKA were 0.1 (n = 5), <0.1 (n = 1) and 0.1 (n = 5) per 100 patient-years with empagliflozin 10 and 25 mg and placebo, respectively. 13 In clinical trials of canagliflozin (n = 17 596), incidence rates of DKA and related events were 0.52 (n = 4), 0.76 (n = 6), and 0.24 (n = 2) per 1000 patient-years with canagliflozin 100 and 300 mg and comparator, respectively. 34 The majority of canagliflozin-treated patients reporting serious DKA had associated precipitating factors such as non-compliance with insulin therapy, and 6 of the 10 canagliflozin-treated patients indicated evidence of autoimmune diabetes (ie, type 1 diabetes, etc.).
35
A low frequency of amputation was observed in dapagliflozinand placebo-/active comparator-treated patients; however, the number of patients with amputation events was too low to draw any conclusions based on the differences observed in baseline characteristics. Bladder cancer is another safety issue that has been previously explored, owing to a numerical imbalance observed between dapagliflozin-and control-treated patients in the new drug application submitted to the US FDA in 2011. 36 In an updated analysis of >9000 patients in the phase IIb/III dapagliflozin trials, 9/5936 and 1/3403 dapagliflozin-and comparator-treated patients, respectively, reported bladder cancer, with an incident rate ratio of 5.168 (95% CI 0.68-233.55). 37 The totality of the data, with a small number of bladder cancer cases and the lack of carcinogenic potential of dapagliflozin in preclinical studies, does not support a causal relationship between dapagliflozin and increased bladder cancer risk. There was however, the possibility of ascertainment bias possibly because of a thorough investigation of microhaematuria from the time of randomization. Bladder cancer is being further assessed in a post-authorization safety study and the DECLARE-TIMI 58 (NCT01730534) trial.
This pooled analysis included treatment-naïve patients and those receiving multiple background therapies including insulin. All analyses included data after the initiation of rescue therapy. It is possible that background therapies may have contributed to the incidence of some AEs, in particular hypoglycaemia. Another limitation was that the data were collected from clinical trials and because real-world patients do not always fit the profile of those included in clinical trials, findings from this analysis should be applied to the real world with caution.
In conclusion, overall, the proportion of patients experiencing AEs, 
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